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Abstract 
Background: Protoberberine alkaloids are bioactive molecules abundant in plant preparations for traditional 
medicines. Yeast engineered to express biosynthetic pathways for fermentative production of these compounds will 
further enable investigation of the medicinal properties of these molecules and development of alkaloid-based drugs 
with improved efficacy and safety. Here, we describe the optimization of a biosynthetic pathway in Saccharomyces 
cerevisiae for conversion of rac-norlaudanosoline to the protoberberine alkaloid (S)-canadine.
Results: This yeast strain is engineered to express seven heterologous enzymes, resulting in protoberberine alkaloid 
production from a simple benzylisoquinoline alkaloid precursor. The seven enzymes include three membrane-bound 
enzymes: the flavin-dependent oxidase berberine bridge enzyme, the cytochrome P450 canadine synthase, and a 
cytochrome P450 reductase. A number of strategies were implemented to improve flux through the pathway, includ-
ing enzyme variant screening, genetic copy number variation, and culture optimization, that led to an over 70-fold 
increase in canadine titer up to 1.8 mg/L. Increased canadine titers enable extension of the pathway to produce ber-
berine, a major constituent of several traditional medicines, for the first time in a microbial host. We also demonstrate 
that this strain is viable at pilot scale.
Conclusions: By applying metabolic engineering and synthetic biology strategies for increased conversion of simple 
benzylisoquinoline alkaloids to complex protoberberine alkaloids, this work will facilitate chemoenzymatic synthesis 
or de novo biosynthesis of these and other high-value compounds using a microbial cell factory.
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Background
Alkaloids are nitrogen heterocycle-containing metab-
olites derived from amino acids. Alkaloids have 
wide-ranging chemical structures and bioactivities. Ben-
zylisoquinoline alkaloids  (BIAs) are a structural class of 
l-tyrosine derived plant alkaloids, including morphi-
nan, protoberberine, and benzophenanthridine alka-
loids. Protoberberine alkaloids occur in at least thirteen 
families of flowering plants, with the barberry, moon 
seed, poppy, and buttercup families comprising the most 
researched natural producers of these molecules [1]. Chi-
nese, Indian, Islamic, and Native American traditional 
medicines all use plants in these families. Protoberberine 
alkaloids possess many reported bioactivities, including 
amelioration of multiple sclerosis in a mouse model [2], 
mitochondrially-mediated arrest of cell proliferation [3], 
and decreased blood sugar and cholesterol in diabetic 
patients [4].
Obtaining BIAs directly from their natural producers 
limits our ability to investigate the medicinal properties 
of many individual molecules and develop alkaloid-based 
drugs with improved efficacy, safety, and pharmacody-
namics [5, 6]. First, only molecules that accumulate in 
crop plants are accessible. For example, morphine-pro-
ducing cultivars of opium poppy accumulate morphine 
and codeine, but not upstream intermediates such as 
salutaridine. The concentrations of molecules that do 
accumulate vary with geography and climate, cultivation 
and harvest methods, plant material storage and process-
ing, and the portions of the plant used. Second, purify-
ing a molecule of interest from plant material requires 
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intensive mechanical and chemical processing. Third, 
natural bioactive molecules often lack appropriate func-
tional groups for derivatization to enable structure–
activity studies.
Current alternatives to plant-based production of 
BIAs are plant cell culture and chemical or chemoenzy-
matic synthesis. For example, berberine is commercially 
produced via plant cell culture [7]. However, due to dif-
ferences in enzyme expression, the in planta alkaloid 
profile differs from the plant cell culture alkaloid profile, 
and many alkaloids cannot be produced in cell culture. 
Furthermore, plant cell culture strains take longer to 
develop and have limited productivity relative to com-
mon industrial microbes because plant cells have longer 
generation times and are more difficult to genetically 
modify. Chemical or chemoenzymatic synthesis of BIAs 
enables production of bioactive molecules or intermedi-
ates of interest in a controlled, plant source-independent 
manner, effectively eliminating the challenges described 
above. However, the chemical synthesis of BIAs, includ-
ing protoberberine alkaloids, is often challenging due to 
the presence of chiral centers, fused ring systems, and 
regiochemistry of ring substitutions and oxidations. 
This chemical complexity requires step-intensive routes, 
reducing yields [8]. In contrast, biocatalysis enables ste-
reo- and regio-selectivity. For example, a chemoenzy-
matic route to (S)-scoulerine and (R)-reticuline included 
berberine bridge enzyme (BBE) to catalyze berberine 
bridge formation and kinetically resolve the (R)-enanti-
omer of reticuline [9].
Heterologous expression of multi-step biosynthetic 
pathways in a microbial host enables fermentative pro-
duction or conversion of complex molecules in a single 
vessel, increasing yield by eliminating intermediate isola-
tion steps. Engineered Escherichia coli cultures produced 
(S)-reticuline from dopamine [10] and later from glyc-
erol [11] at titers up to 34 mg/L and productivity up to 
0.57 mg/L/h [12]. The production of the protoberberine 
alkaloid (S)-scoulerine was also reported using a cocul-
ture of the reticuline-producing E. coli and BBE-express-
ing S. cerevisiae [10]. The downstream protoberberine 
(S)-canadine was produced from rac-norlaudanosoline 
(tetrahydropapaveroline) by an engineered yeast strain 
expressing seven heterologous genes encoding enzymes 
from Thalictrum flavum, Papapver somniferum, and 
Arabidopsis thaliana [13]. As a eukaryotic host organ-
ism, S. cerevisiae can support the functional expression 
of membrane-bound enzymes such as the flavoenzyme 
BBE and the cytochrome P450 oxidoreductase (P450) 
canadine synthase (CAS). Yeast strains can be efficiently 
engineered by in vivo assembly of episomal and chromo-
somally-integrated constructs, due to robust endogenous 
homologous recombination machinery. Furthermore, 
fermentation with engineered yeast is a scalable platform 
for production of complex plant alkaloids [5].
Here, we report the first heterologous production 
of berberine and the optimization of the engineered 
biosynthetic pathway from rac-norlaudanosoline to 
(S)-canadine in yeast (Scheme  1). The plant pathway 
includes three classes of membrane-associated enzymes: 
cytochrome P450 oxidorecuctase (P450), flavin-depend-
ent oxidase, and cytochrome P450 reductase (CPR). We 
characterized P450 expression by fluorescence micros-
copy, optimized expression levels and stability via strain 















































































Scheme 1 Heterologous berberine biosynthetic pathway from nor-
laudanosoline. Shown is the conversion of rac-norlaudanosoline to 
(S)-reticuline via the SAM-dependent methyltransferases norcoclau-
rine 6-O-methyltransferase (6OMT), 3′-hydroxy-N-methylcoclaurine 
4′-O-methyltransferase (4′OMT), and coclaurine-N-methyltransferase 
(CNMT), and to the protoberberine alkaloids (S)-scoulerine via berber-
ine bridge enzyme (BBE), (S)-tetrahydrocolumbamine via scoulerine 
9-O-methyltransferase (S9OMT), (S)-canadine via canadine synthase 
(CAS) and its reductase partner cytochrome P450 reductase (CPR), 
and berberine via (S)-tetrahydroprotoberberine oxidase (STOX) or 
spontaneous oxidation
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enzymes from a variety of plant sources to increase 
protoberberine alkaloid titers. Media and culture con-
dition optimization further increased titers. Overall, 
we increased the titer of (S)-canadine by greater than 
70-fold relative to our previously reported strain, up to 
1.8 mg/L, and were able to make berberine for the first 
time. A pilot scale 0.2-L bioreactor experiment resulted 
in titers of 0.7  mg/L canadine and 39  μg/L berberine. 
This (S)-canadine producing strain will enable heter-
ologous biosynthesis of other protoberberine, berber-
ine, and phthalide isoquinoline alkaloids for elucidating 
biosynthetic routes and, with further optimization, for 
industrial production.
Results and discussion
Cytochrome P450 expression engineering to improve 
(S)‑canadine biosynthesis
Our laboratory previously engineered a S. cerevisiae 
W303α strain to biosynthesize (S)-canadine from the 
fed precursor (R, S)-norlaudanosoline [13]. This cana-
dine-producing yeast strain (CSY410, Table  1) harbors 
expression cassettes for seven heterologous enzymes: 
P. somniferum norcoclaurine 6-O-methyltransferase 
(Ps6OMT, AAP45315), P. somniferum 3′-hydroxy-
N-methylcoclaurine 4′-O-methyltransferase 2 (Ps4′OMT, 
AAP45314), P. somniferum coclaurine N-methyltrans-
ferase (PsCNMT, AAP45316), P. somniferum berberine 
bridge enzyme (PsBBE, AAC61839), T. flavum scoulerine 
9-O-methyltransferase (TfS9OMT, AAU20770), T. fla-
vum canadine synthase (TfCAS, AAU20771), and A. thal-
iana cytochrome P450 reductase 1 (CPR, AAK96879). 
The expression cassettes for the methyltransferases 
Ps6OMT, PsCNMT, and Ps4′OMT and the cytochrome 
P450 reductase CPR were chromosomally integrated, 
TfS9OMT and TfCAS were expressed from a high-copy 
plasmid (HCP), and PsBBE was expressed from a second 
HCP. All coding sequences were preceded by variants of 
the yeast TEF1 promoter. To access berberine and other 
downstream products, such as noscapine, we optimized 
the (S)-canadine-producing strain.
To improve flux through the pathway, we first imple-
mented two optimization strategies based on previous 
work in our laboratory [14]: increasing construct stabil-
ity via integration and expressing the plant cytochrome 
P450 with an optimized regulatory profile. The first was 
implemented by integrating PsBBE into the chromo-
some instead of expressing from a HCP and the second 
by using the TDH3 promoter (PTDH3) rather than the 
TEF1 promoter (PTEF1) for P450 expression. Strains were 
assayed by analyzing the media supernatant by LC–MS/
MS after 96 h culture with 2 mM norlaudanosoline. Reti-
culine, canadine, and berberine were identified by com-
parison of retention time and product ion spectra to 
authentic standards (Additional file 1: Fig. S1). The inter-
mediates scoulerine and tetrahydrocolumbamine were 
identified by comparison of product ion spectra or MRM 
transitions to published LC–MS/MS analyses [15].
Chromosomal integration of PsBBE slightly increased 
canadine production (CSY1011, Fig.  1a) relative to 
the original strain (CSY410), but with high variance. 
PTDH3-based expression of TfCAS on a HCP (CSY1012) 
decreased flux relative to PTEF1-based expression on a 
HCP (CSY1011). Canadine synthase is a microsomal 
heme-thiolate cytochrome P450 oxidoreductase that is 
N-terminally embedded in the endoplasmic reticulum 
(ER) membrane with the catalytic domain facing the 
cytoplasm [16]. The cytochrome P450 reductase, which 
transfers electrons from NADPH to the P450 in order 
to complete the heme catalytic cycle, is also N-termi-
nally embedded in the ER. Therefore, properly local-
ized expression is critical to heterologous microsomal 
P450 and P450 reductase activities, unless the enzymes 
are engineered to function without their localization 
domains. Live cell confocal fluorescence microscopy pro-
vided useful insights into the localization and qualitative 
expression level of a P450 in a similar multi-step heter-
ologous pathway [14]. Thus, we imaged C-terminally 
EGFP-tagged TfCAS expressed from a HCP, low-copy 
plasmid (LCP), and chromosomal integration to deter-
mine TfCAS localization and expression levels (Fig. 1b). 
Neither the chromosomally integrated GFP control 
nor the integrated TfCAS-GFP construct was detect-
able above autofluorescence by fluorescence microscopy. 
Even though DNA copy number is equivalent for chro-
mosomal integration and low-copy plasmid and genomic 
integration is more stable across the population, we 
have observed differences in fluorescence microscopy 
for GFP and other proteins in our laboratory, with chro-
mosomal integration generally giving the same or lower 
fluorescence and activity. Additionally, we have seen dif-
ferences in GFP fluorescence depending on the specific 
locus selected for integration. We believe the differences 
observed for GFP and TfCAS-GFP fluorescence between 
low-copy and integrated strains is due to lower expres-
sion from the integrated constructs resulting from the 
genomic context, chromosomal topology, and possible 
epigenetic silencing. With both LCP- and HCP-based 
expression, the GFP control fluorescence was detectable 
in 24–27  % of the imaged yeast cells. The TfCAS-GFP 
fusion was detected in a similar fraction of cells when 
expressed from a LCP, but only half as many as the con-
trol when expressed from a HCP. This suggests that high-
copy expression of the P450 stresses the yeast host cell, 
which responds by reducing expression or eliminating 
the plasmid, despite growing the yeast under auxotrophic 
selective pressure.
Page 4 of 13Galanie and Smolke  Microb Cell Fact  (2015) 14:144 
Table 1 S. cerevisiae strains and plasmids used in this study
Plasmid Description Source
pCS6 pRS314, CEN/ARS vector, TRP1 selectable marker [50]
pCS8 pRS316, CEN/ARS vector, URA3 selectable marker [50]
pCS952 2 μ vector, PTEF1-TfS9OMT-TCYC1, URA3 selectable marker [13]
pCS953 2 μ vector, PTEF1-TfS9OMT-TCYC1, PTEF1-TfCAS-TCYC1, URA3 selectable marker [13]
pCS1018 2 μ vector, PTEF1-PsBBE-TCYC1, TRP1 selectable marker [13]
pCS3194 2 μ vector, PTDH3-repaired TfCAS-EGFP-TCYC1, TRP1 selectable marker This work
pCS3195 CEN/ARS vector, PTDH3-repaired TfCAS-EGFP-TCYC1, TRP1 selectable marker This work
pCS3196 CEN/ARS vector, PTDH3-EGFP-TCYC1, TRP1 selectable marker This work
pCS3197 2 μ vector, PTDH3-EGFP-TCYC1, TRP1 selectable marker This work
pCS3070 CEN/ARS vector, PTDH3-repaired TfCAS-TCYC1, TRP1 selectable marker This work
pCS3071 CEN/ARS vector, PTDH3-TfCAS from pCS952-TCYC1, TRP1 selectable marker This work
pCS3072 2 μ vector, PTDH3-TfCAS from pCS952-TCYC1, TRP1 selectable marker This work
pCS3409 CEN/ARS vector, PTEF1-repaired TfCAS-TCYC1, TRP1 selectable marker This work
pCS3100 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-TfS9OMT-TCYC1, PTDH3-TfCAS-TADH1, TRP1 selectable marker This work
pCS3198 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yCjS9OMT-TCYC1, PTDH3-TfCAS-TADH1, TRP1 selectable marker This work
pCS3199 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-TfCAS-TADH1, TRP1 selectable marker This work
pCS3200 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-yPsCAS-TADH1, TRP1 selectable marker This work
pCS3201 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-yAmCAS-TADH1, TRP1 selectable marker This work
pCS3202 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-yCjCAS-TADH1, TRP1 selectable marker This work
pCS3203 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-yCjCAS-TADH1, PTPI1-yBwSTOX-TSTE2, TRP1 selectable marker This work
pCS3204 YAC vector pYES1L, PPGK1-PsBBE-TPHO5, PTEF1-yPsS9OMT-TCYC1, PTDH3-yCjCAS-TADH1, PHXT7-yBwSTOX-TPGK1, TRP1 selectable marker This work
Strain Description Source
CSY3 W303 (Matα, ade2–1 ura3–1 his3–11, 15 trp1–1 leu2–3, 112 can 1–100) K. Weis
CSY288 CSY3 his3::PTEF1-Ps6OMT-TCYC1, leu2::PTEF1-PsCNMT-TCYC1, ura3::PTEF1-Ps4′OMT-TCYC1 [13]
CSY410 CSY288 trp1::PTEF1-CPR-TCYC1, pCS953, pCS1018 [13]
CSY835 CSY288 trp1::PTEF1-CPR-TCYC1 This work
CSY844 CSY288 trp1::PTEF1-CPR-TCYC1, lys2::PTEF1-PsBBE-TCYC1 [14]
CSY1005 CSY3, pCS3194 This work
CSY1006 CSY3, pCS3195 This work
CSY1007 CSY3 fcy1::PTDH3-TfCAS-EGFP-TCYC1, pCS6 This work
CSY1008 CSY3, pCS3196 This work
CSY1009 CSY3, pCS3197 This work
CSY1010 CSY3 fcy1::PTDH3-EGFP-TCYC1, pCS6 This work
CSY1011 CSY844, pCS6, pCS953 This work
CSY1012 CSY844, pCS952, pCS3072 This work
CSY1013 CSY844, pCS952, pCS3071 This work
CSY1083 CSY844, pCS952, pCS3409 This work
CSY1014 CSY844, pCS952, pCS3070 This work
CSY1016 CSY835, pCS8, pCS3100 This work
CSY1017 CSY844, pCS8, pCS3100 This work
CSY1018 CSY844, pCS8, pCS3198 This work
CSY1019 CSY844, pCS8, pCS3199 This work
CSY1020 CSY844, pCS952, pCS3199 This work
CSY1021 CSY844, pCS952, pCS3200 This work
CSY1022 CSY844, pCS952, pCS3201 This work
CSY1023 CSY844, pCS952, pCS3202 This work
CSY1024 CSY844 XI-3::PTEF1-yCjCAS-TCYC1, pCS952, pCS3202 XI-3 locus 
from [51]
This work
CSY1025 CSY844, pCS952, pCS3203 This work
CSY1026 CSY844, pCS952, pCS3204 This work
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Membrane-bound patterns of expression, which differ 
from the cytosolic expression of the GFP control, were 
observed for TfCAS-GFP expressed from both the HCP 
and LCP. However, small, highly saturated fluorescent 
regions were observed when TfCAS-GFP was expressed 
from a HCP in contrast to expression from a LCP. These 
saturated regions are likely indicative of protein aggre-
gation or ER-associated degradation [17]. The imag-
ing results suggest that lowering the expression level of 
TfCAS would increase the overall functional expression 
of the enzyme and therefore conversion efficiency from 
tetrahydrocolumbamine to canadine.
When TfCAS was expressed from PTDH3 on a LCP 
(CSY1013, Fig. 1a), canadine titer was increased 1.7-fold 
relative to HCP (CSY1012). These results are consist-
ent with the hypothesis that the pattern of fluorescence 
observed from HCP expression through microscopy 
is detrimental to functional expression. Expression of 
TfCAS from a chromosomally integrated construct pro-
duced only trace levels of canadine, below the limit of 
quantitation. Similar to our observation for integrated 
GFP and TfCAS-GFP, we attribute this result to lower 
expression from the integrated construct relative to 
LCP. Additional improvement in canadine production 
was obtained by identifying an amino acid in TfCAS in 
the original yeast strain that differed from the depos-
ited sequence and mutating this residue to correspond 
to the original sequence (CSY1014). In order to directly 
examine the effect of promoter choice in this context, we 
made a strain identical to CSY1014 with the TEF1 pro-
moter cloned in place of the TDH3 for expression of the 
repaired TfCAS. We found that this new strain produced 
much less canadine than CSY1014, demonstrating that 
the TDH3 promoter is better for TfCAS expression in 
this context. Taken together, these modifications resulted 
in a 4.4-fold increase in canadine titer relative to the orig-
inal yeast strain (CSY410).
Copy number and enzyme variant engineering  
to improve protoberberine alkaloid production
Approaches for tuning enzyme expression timing and 
levels, such as expression induction, promoter selec-
tion, and genetic copy number, can be used to balance 
flux through heterologous pathways. To reduce the 
number of auxotrophies needed for maintaining path-
way enzymes, facilitate genetic copy number engineer-
ing, and simplify pathway assembly for rapidly testing 
various combinations of promoters and enzyme vari-
ants, we consolidated several pathway genes onto a yeast 
artificial chromosome (YAC). We anticipated that YACs 
would exhibit similar advantages as LCPs over HCPs for 
functional expression of cytochrome P450s and other 
membrane-bound enzymes, such as BBE. We rapidly 
assembled YACs in  vivo in yeast from PCR-amplified 
expression cassettes and pYES1L backbone [18] using 
the strong glycolytic promoters PPGK1 and PTDH3 and 
the strong constitutive promoter PTEF1. The initial YAC, 
pCS3100, was assembled from PTEF1-TfS9OMT, PPGK1-
PsBBE, and PTDH3-TfCAS cassettes in the strain with the 
Ps6OMT, PsCNMT, Ps4′OMT, and CPR expression cas-
settes chromosomally integrated (CSY1016). pCS3100 
was also characterized in a similar strain background 
Fig. 1 DNA copy number optimization and site directed mutagenesis of CAS for increased canadine titer. a (S)-canadine titers for S. cerevisiae 
expressing the protoberberine biosynthetic pathway with varied TfCAS constructs (Table 1). Int, chromosomally integrated; HCP, high copy plasmid; 
LCP, low copy plasmid. LC–MS/MS analysis was performed on media supernatant collected after 96 h of cultivation in YNB-DO (2 % dextrose) with 
2 mM rac-norlaudanosoline. Error bars represent mean values ±1 SD of at least three biological replicates. b Confocal fluorescence microscopy 
images of TfCAS-GFP and GFP control. Percentages indicate the percent of cells that were fluorescent out of at least 300 cells counted from three 
separate clonal cultures. Scale bars 5 μm
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with a second copy of PsBBE chromosomally integrated 
(CSY1017). CSY1016 and 1017 produced less canadine 
than CSY1014 (Fig. 2a). Scoulerine accumulated in both 
of these strains (Additional file 1: Fig. S2), indicating that 
the TfS9OMT-catalyzed step was inefficient.
In CSY410, TfS9OMT was expressed from a HCP; 
thus we attributed the decreased canadine titers to 
the decreased expression of TfS9OMT on the YAC. To 
address the decreased S9OMT enzyme activity, we first 
examined whether other variants of the enzyme exhibit 
greater activity in the heterologous yeast host. We iden-
tified known orthologs by performing a protein BLAST 
search with TfS9OMT as the query (Additional file  2: 
Table S2). We replaced TfS9OMT in CSY1017 with yeast 
codon-optimized S9OMT genes from two other plants, P. 
somniferum (yPsS9OMT, AFB74611) and Coptis japonica 
(yCjS9OMT, Q39522). The yPsS9OMT strain CSY1019 
produced 2.6-fold more canadine than the TfS9OMT 
strain CSY1017, whereas the yCjS9OMT strain CSY1018 
produced less. As unconverted scoulerine was still 
observed in CSY1019 (Additional file 1: Fig. S2), an addi-
tional copy of TfS9OMT expressed from a HCP was added 
to the system to make strain CSY1020. CSY1020 exhibited 
less unconverted scoulerine, greater accumulation of the 
intermediate tetrahydrocolumbamine, yet little increase 
in canadine production (Additional file 1: Fig. S2).
To increase conversion from tetrahydrocolum-
bamine to canadine, we implemented a similar strategy 
to increase CAS activity, by examining enzyme variants 
from different plants for increased activity and additional 
gene copies for increased pathway flux (Additional file 2: 
Table S2). The yeast codon-optimized genes tested were 
from C. japonica (yCjCAS, Q948Y1), Argemone mexi-
cana (yAmCAS, B1NF19), and P. somniferum (yPsCAS, 
ADB89214). The yPsCAS strain CSY1021 produced only 
trace amounts of canadine, indicating that this enzyme 
acts exclusively as a stylopine synthase and has little 
activity on tetrahydrocolumbamine [19]. The yAmCAS 
strain (CSY1022) produced about the same amount of 
canadine, and the yCjCAS (CSY1023) strain produced 
11-fold more canadine than TfCAS strain CSY1020 
(Fig.  2b). No further improvements in canadine titers 
were obtained by expressing a second copy of yCjCAS 
via chromosomal integration (CSY1024). While not all 
of the CAS enzyme variants that we assayed have been 
biochemically characterized, yCjCAS has the lowest Km 
of the characterized variants, suggesting that it has the 
strictest substrate specificity [16]. Thus, the superior per-
formance of the yCjCAS enzyme in our strains may be 
explained by increased substrate binding and specificity, 
and therefore increased pathway flux and reduced forma-
tion of side products.
Spontaneous production of berberine
Berberine is used in traditional Chinese and Japanese 
medicine in its pure form and as part of Coptis chinen-
sis or Huang Lian Su extract. Berberine is also found 
in Hydrastis canadensis, or goldenseal, and Berberis 
aristata, or Indian barberry, extracts used in Native 
American and Ayurvedic traditional medicines, respec-
tively. Berberine is commercially produced by plant cell 
culture, but microbial biosynthesis can potentially exceed 
the productivity of plant cell culture due to decreased 
doubling times [7]. The enzyme that catalyzes the 4-elec-
tron oxidation of canadine to form berberine, (S)-tet-
rahydroprotoberberine oxidase (STOX), was recently 
cloned and characterized [20].
We assembled an expression cassette containing yeast 
codon-optimized Berberis wilsonae STOX (yBwSTOX) 
into pCS3203 with either the strong glycolytic promoter 
Fig. 2 Enzyme variant and DNA copy number optimization of S9OMT and CAS for increased canadine titer. a S9OMT. b CAS. Strains listed in Table 1. 
LC–MS/MS analysis was performed on media supernatant collected after 96 h of cultivation in YNB-DO (2 % dextrose) with 2 mM rac-norlaudano-
soline. Error bars represent mean values ±1 SD of at least three biological replicates
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PTPI1 or the late-stage dextrose-repressed promoter PHXT7 
to make strains CSY1025 and CSY1026, respectively. 
Following culture with norlaudanosoline, berberine was 
detected in the media from both strains, and its identity 
was confirmed by LC–MS/MS comparison to an authen-
tic standard (Fig. 3a). Berberine was also detected at the 
same level in strain CSY1023 without yBwSTOX. We 
also observed gradual formation of berberine in cana-
dine standards. We observe no significant increase in the 
strains with STOX relative to the strains without STOX, 
therefore all of the observed conversion could be attrib-
uted to non-enzymatic oxidation of canadine to berber-
ine in aqueous solution. This non-enzymatic oxidation 
was also recently observed for the conversion of dihydro-
sanguinarine to sanguinarine [14, 21] and oxidation of 
13,14-dihydrocoptisine to coptisine [22]. An earlier study 
showed that recombinant STOX expressed in Sf9 insect 
cells catalyzed conversion of canadine added directly to 
cell cultures to berberine [20], so we hypothesize that 
improving the functional heterologous expression of 
STOX in yeast would allow us to observe enzymatic oxi-
dation, thereby increasing production of berberine. How-
ever, as the observed spontaneous formation of berberine 
suggests, canadine can also be readily converted to ber-
berine chemically.
We implemented modifications to the host back-
ground that were directed to decreasing protein deg-
radation rates by knocking out two endogenous yeast 
vacuolar protease genes, proteinase A (PEP4) and pro-
teinase B (PRB1) [23]. Neither the single nor double 
knockouts improved canadine or berberine titers. We 
also examined the effect of lowering cytochrome P450 
reductase (CPR) expression levels using the TEF1 pro-
moter mutant series [24] on canadine titers. We found 
that the wild type TEF1 and TDH3 promoters resulted in 
the highest canadine titers, with all of the lower expres-
sion mutant promoters decreasing titer (Additional file 1: 
Fig. S3). Therefore, strains CSY1023, 1025, and 1026 were 
able to convert the most rac-norlaudanosoline to (S)-
canadine with a titer of 930 and <3 μg/L berberine titer 
after 96 h growth in culture tubes.
Optimization of batch fermentation for protoberberine 
alkaloid production
To optimize batch fermentation conditions for greater 
protoberberine production and facilitate scale up, we 
explored the impact of pH, temperature, and sugar on 
canadine and berberine titers of strain CSY1025, which 
produced the most canadine. These experiments were 
performed in 12.5 mL cultures in shake flasks. The media 
pH was either allowed to acidify normally during cultiva-
tion or controlled by inclusion of 60 mM citrate buffer at 
pH 5.7. Temperature was held at 30 or 25 °C, and the car-
bon source was 2 % dextrose or 2 % galactose. The total 
canadine and berberine titers were quantified by LC–
MS/MS by measuring the concentration in the media 
supernatant of cultures grown with 1 mM rac-norlauda-
nosoline. Buffering the media and using galactose as the 
sugar had the largest positive impact on titers, increasing 
the combined canadine and berberine titer 2.5-fold for 
buffered relative to unbuffered with dextrose and 1.9-fold 
for galactose relative to dextrose (Fig.  3b). Temperature 
did not significantly affect titers. With optimized culture 
conditions, the titers for canadine and berberine were 
1.8 mg/L and 6.5 μg/L, respectively.
Maintaining higher pH conditions throughout the 
fermentation (5–5.7 for buffered media vs 3.5–5.7 for 
unbuffered media) likely improves titers because the 
Fig. 3 LC–MS/MS analysis and culture optimization of berberine-producing yeast strain. a LC–MS/MS chromatogram of berberine produced in the 
media supernatant of engineered strain CSY1025 after 96 h cultivation in YNB-DO (2 % dextrose) and of an authentic berberine standard. The peak 
heights are normalized to the height of the standard. b Effects of pH, sugar, and temperature on canadine titers. LC–MS/MS analysis was performed 
on media supernatant collected after 96 h of cultivation in YNB-DO (2 % dextrose) with 1 mM rac-norlaudanosoline in 12.5 mL shake flask cultures. 
Error bars represent range of two biological replicates
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plant enzymes have pH optima of 7.5–9 [15, 25–27]. 
Although yeast can grow at pH 7–7.5, the norlaudano-
soline substrate is oxidatively unstable at pH above 6.5 
due to the catechol moieties. Therefore, we anticipate 
that engineering yeast strains for de novo production, 
as was recently accomplished for the plant-derived alka-
loid strictosidine [28], will allow for even greater product 
titers by eliminating the need to feed norlaudanosoline 
and allowing the process to be performed at neutral pH.
The positive impact of galactose on alkaloid titers of 
engineered yeast strains was previously noted [14]. Metab-
olizing galactose instead of dextrose changes gene expres-
sion in several yeast pathways, but it is not clear which of 
these effects are related to the improved titers [29]. Galac-
tose can also be converted into l-ascorbic acid by yeast 
[30], and the antioxidant ascorbic acid was previously 
reported to stabilize norlaudanosoline in E. coli cultures 
[31]. However, including 10  mM ascorbic acid in culture 
media did not impact product titers (data not shown).
Pilot scale batch and fed‑batch cultivation 
of protoberberine‑producing strain
To further evaluate the engineered strain CSY1025 for 
protoberberine production from rac-norlaudanosoline, 
0.2-L pilot scale batch fermentations were performed 
in a bioreactor. Based on results from the shake flask 
experiments, citrate buffer was included in the media 
and 30  °C growth temperature was maintained. Despite 
the improvement observed with galactose in shake flasks, 
we used dextrose in the bioreactor runs because of its 
greater ability to support rapid biomass accumulation. 
Final titers of 621 μg/L canadine and 27 μg/L berberine 
were obtained after 72 h of batch cultivation with a final 
OD of only 5.2 (Fig. 4a). This canadine titer was 67 % of 
what was observed in culture tubes and shake flasks, and 
the berberine titer was nearly tenfold higher than what 
was observed in tubes and flasks. Canadine production 
was highly growth associated, so we investigated whether 
increasing strain growth would also increase canadine 
production by performing a fed-batch fermentation.
Because we observed low ODs in the batch fermenta-
tion, we hypothesized that biomass was limiting to sub-
strate conversion. For fed-batch conditions, 10× of the 
same media without buffer was fed at a rate of 20 mL/day 
starting at 24 h. Fed-batch conditions increased the strain 
OD up to 10.6 with a 13  % increase in canadine titer 
and a 44  % increase in berberine titer (Fig.  4b). Given 
the variation between fermentations, there is not a sig-
nificant difference between the canadine titers obtained 
in batch relative to fed-batch. When dilution by the feed 
volume is taken into account, this corresponds to a 41 % 
increase in the overall amount of canadine and an 81 % 
increase in the amount of berberine. Since increasing 
the ODs by fed-batch fermentation did not significantly 
improve titers, we concluded that the specific productiv-
ity of the strains, rather than or jointly with the biomass 
concentration, requires further optimization. The lack of 
correlation between conditions that yield high biomass 
and conditions that yield high product titers has been 
observed previously [32]. Further increases in canadine 
titer may be obtained by engineering the yCjCAS enzyme 
to relieve any product inhibition, making further changes 
to yeast metabolism to obtain redox balance, and engi-
neering the heterologous pathway and native metabo-
lism to reduce any diversion of canadine to other side 
products. The spontaneous formation of berberine from 
canadine was low (<7 %), and is increased in the bioreac-
tor relative to shake flasks, likely due to increased oxygen 
transfer rate for the bioreactor relative to flasks. A larger 
reactor would have a reduced oxygen transfer rate, and 
aeration can be further tuned by modulating stir speed 
and purging rate. Therefore, we do not anticipate spon-
taneous formation of berberine to be a major limitation 
to producing canadine derivatives. Improved functional 
expression of yBwSTOX would increase flux to berberine, 
and connecting this pathway to upstream metabolism for 
Fig. 4 Pilot scale fermentation of engineered S. cerevisiae strain CSY1025. a Pilot scale batch and b fed-batch 0.2-L fermentations in bioreactor with 
YNB-DO (2 % dextrose) with 1 mM rac-norlaudanosoline. Canadine and berberine titers were determined by LC–MS/MS from sample supernatant at 
indicated time points. Error bars represent the range of two independent fermentations
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de novo production would allow us to fully optimize car-
bon use and redox balance to maximize flux through the 
pathway.
The current optimized yeast strain with 70-fold higher 
titer of (S)-canadine would result in ~70-fold decrease 
in process cost relative to the previously reported yeast 
strain [13]. For plant cell culture, the estimated break 
even point for a product selling cost, inflation adjusted, 
is ~$2800/kg [33]. Berberine currently sells for ~$6000/
kg and (S)-canadine is only available as a specialty chemi-
cal, selling for ~$4800/g. The industrial plant cell culture 
process is based on a fed-batch culture of Coptis japon-
ica cells, which can reach a berberine titer of 3.5  g/L 
after 14  days of culture [34]. (S)-canadine, of value for 
stereospecific synthesis of phthalideisoquinoline alka-
loids, is not accessible by plant culture because of high 
conversion to berberine. At these selling price points, 
a microbial fermentation titer of 1–2  g/L is needed for 
production of berberine, and even lower for canadine 
[35]. The yeast process reported here produces 1.8 mg/L 
canadine after 4  days of culture. Combining the engi-
neered strain reported here with a strain reported to 
produce (S)-reticuline from sugar [36, 37] and conduct-
ing further research for the necessary strain, pathway, 
and fermentation improvements to obtain a canadine 
titer of 60–200 mg/L, similar to the industrial processes 
for paclitaxel and vitamin B12 [38, 39], could result in 
an industrially relevant process. Additionally, establish-
ing the plant cell culture inoculum takes up to a month, 
while a yeast inoculum requires only 24 h [40]. In plant 
cell culture, alkaloids accumulate in vacuoles, so down-
stream processing requires cell disruption, solid–liquid 
separation, and product recovery. In yeast culture, the 
alkaloids accumulate in the media rather than in the cells, 
so cell disruption is not required, reducing processing by 
one unit operation. Overall, with further development 
yeast fermentation could achieve cost savings by decreas-
ing fermentation time and simplifying downstream 
processing.
Conclusions
In this work, we optimized the reconstituted seven-
enzyme pathway, including three types of membrane-
bound enzymes, to convert the commercially available 
and synthetically accessible substrate rac-norlaudano-
soline to the protoberberine alkaloid (S)-canadine and 
the medicinal compound berberine. We optimized this 
pathway by examining the effects of DNA copy number, 
enzymes from different plant sources, and culture con-
ditions. Consistent with previous reports, we observed 
greater cytochrome P450 activity when expressed from 
1 to 2 DNA copies with a glycolytic promoter [14]. Ulti-
mately, the best yields were obtained by using enzymes 
from a variety of plant sources and combining YAC-, 
chromosome-, and high-copy plasmid-based expres-
sion. The strain and culture engineering resulted in an 
over 70-fold increase in the canadine titer relative to the 
original strain, and we demonstrated that similar titers 
could be achieved in a pilot scale bioreactor. (S)-canadine 
is useful as a precursor for a number of chiral alkaloids, 
including the phthalideisoquinoline alkaloid noscapine, a 
potential anticancer drug [41]. This work also describes 
the first heterologous production of berberine, which was 
produced at more than tenfold greater titer in the biore-
actor than in shake flasks or culture tubes. Our combined 
metabolic engineering and synthetic biology approach 
for in vivo microbial reconstitution of alkaloid biosynthe-
sis is a useful tool for biochemical discovery and fermen-
tative production of complex, high-value molecules.
Methods
Chemicals, media, and cultivation
Difco yeast nitrogen base without amino acids and 
ammonium sulfate (YNB), Bacto peptone, Bacto yeast 
extract, Luria Broth (LB), LB agar, dextrose, and galac-
tose were obtained from Becton, Dickinson and Com-
pany (BD). Kanamycin monosulfate, geneticin sulfate 
(G418), ampicillin, spectinomycin, amino acids, uracil, 
adenine hemisulfate, tris(hydroxymethyl)aminometh-
ane hydrochloride, polysorbate 20 (Tween-20), and citric 
acid were obtained from EMD chemicals. 5-fluoroorotic 
acid (5-FOA) was obtained from Zymo Research. Formic 
acid, acetonitrile, NuPAGE 3-(N-morpholino)propane-
sulfonic acid (MOPS) sodium dodecyl sulfate (SDS) run-
ning buffer, and NuPAGE transfer buffer were obtained 
from Thermo Fisher Scientific. 1-(3,4-dihydroxybenzyl)-
1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrobromide 
(tetrahydropapaveroline or norlaudanosoline, NL) and 
berberine hydrochloride were obtained from Santa Cruz 
Biotechnology (SCBT). (S)-reticuline perchlorate was 
obtained from Specs and d,l-canadine was obtained 
from Apin Chemicals.
Escherichia coli strains were selected on LB agar 
plates with 50  mg/L kanamycin, 50  mg/L ampicillin, or 
100 mg/L spectinomycin and grown in LB liquid media 
with the appropriate antibiotic. Yeast 10× drop out 
(DO) supplement was prepared as 0.2  % adenine hemi-
sulfate, 0.2  % uracil, 1  % l-tryptophan, 1  % l-histidine 
hydrochloride, 1  % l-arginine, 1  % l-methionine, 0.2  % 
l-tyrosine, 1  % l-leucine, 1  % l-isoleucine, 1  % l-lysine 
hydrochloride, 1 % l-phenylalanine, 1 % l-glutamic acid, 
1 % l-aspartic acid, 3 % l-valine, 4 % l-threonine, and 8 % 
l-serine with the desired selection component omitted. 
S. cerevisiae strains were selected on YNB-DO (0.17  % 
yeast nitrogen base, 0.5  % ammonium sulfate, 2  % dex-
trose, and 1× DO) agar or on YPAD (1 % yeast extract, 
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2 % peptone, 80 mg/L adenine hemisulfate, and 2 % dex-
trose) agar with 200  mg/L G418. Yeast were grown in 
selective YNB-DO media or in YPAD media.
Strains and plasmids
Escherichia coli strain TOP10 (Life Technologies) was 
used for cloning and amplification of plasmids. Plasmids 
were recovered using Econospin columns (Epoch Life 
Sciences) according to manufacturer’s instructions. S. 
cerevisiae strain W303α was used as the base strain for 
all engineered strains (Table  1). Oligonucleotide primer 
sequences are provided in Additional file  2: Table S1. 
Oligonucleotides were synthesized by Integrated DNA 
Technologies (IDT) and the Stanford Protein and Nucleic 
Acid Facility. Heterologous gene sequences were cloned 
from previously published plasmids or downloaded from 
Genbank and codon optimized and synthesized by Life 
Technologies or IDT (Additional file 2: Table S2). PCRs 
were performed with PfuUltraII Fusion HS DNA poly-
merase (Agilent Technologies) for <2 kb fragments, Plati-
num Taq PCR SuperMix (Life Technologies) for 2–3 kb 
fragments and for site-directed mutagenesis, or Expand 
High Fidelity PCR system for >3  kb fragments (Roche 
Diagnostics) according to manufacturer’s instructions. 
PCR products were purified by agarose gel extraction 
with Zymoclean gel DNA recovery kit (Zymo Research) 
according to manufacturer’s instructions. Restriction 
enzymes, T4 DNA ligase, and deoxynucleotides were 
purchased from New England Biolabs.
Strains and plasmids used or constructed in this 
work are described in Table  1. Plasmids pCS3070–3072 
and 3194–3197 were constructed by amplifying the 
insert with either a CACC 5′ overhang or 5′ and 3′ BP 
sequences and using the pENTR/D-TOPO cloning kit or 
Gateway BP clonase II and pDONR221 (Life Technolo-
gies), respectively, to create a Gateway entry vector. The 
insert was then cloned into a pAG destination vector 
obtained from Addgene [42] using Gateway LR clonase II 
(Life Technologies). Constructs were verified by sequenc-
ing through the inserted region (Elim Biopharmaceuti-
cals). Plasmids were introduced into yeast by the lithium 
acetate/salmon sperm carrier DNA/polyethylene glycol 
transformation method [43].
Holding vectors were constructed by amplifying the 
backbone, including the promoter and terminator, and 
assembling with the insert via Gibson cloning [44]. 
Expression cassettes were amplified using primers with 
15  bp overhangs for gap repair in yeast. 100  ng each of 
the PCR products and linearized pYES1L (Life Technolo-
gies) were introduced by electroporation into the desired 
yeast background strain to make constructs pCS3100, 
3198, 3199, and 3200–3204 [18, 45]. Plasmids were 
isolated from yeast and amplified in E. coli as previously 
described.
Yeast chromosomal modifications were made using 
either disintegrators [46] or the microhomology gene 
disruption method [47]. For strains CSY1007 and 
CSY1010 the expression cassette was cloned from plas-
mid pCS3070 and pCS3196, respectively, into the KpnI–
SphI restriction sites of plasmid pIS373 [46]. For strains 
CSY1024, the yCjCAS coding sequence was inserted 
between the TEF1 promoter and CYC1 terminator by 
LR recombination into plasmid pCS2641, which is pUG6 
with the promoter and terminator cassette cloned in 
along with the Gateway recombination sites. The disinte-
grators or gene disruption cassettes were introduced into 
yeast by lithium acetate transformation [43]. All selection 
markers were rescued as previously described [46, 47]. 
For the disintegrators, this was done by diluting an over-
night culture to OD600 ~0.4 and plating 250 μL of the 
cell suspension on YNB-DO agar with 1 mg/mL 5-FOA. 
For the microhomology integrations and knockouts, 
selection markers were rescued by loxP recombination. 
All modifications were verified by yeast colony PCR as 
previously described, with the exclusion of gelatin from 
buffers [48].
Confocal microscopy
Single colonies of freshly transformed yeast strains were 
streaked onto YNB-DO agar, grown for 24  h, and then 
inoculated into 3 mL of the appropriate YNB-DO media 
and grown in 16 × 150 mm glass culture tubes for 14 h at 
30 °C in a shaking incubator at 260 rpm. Overnight cul-
tures were back-diluted 1:2 in YNB-DO media and grown 
for an additional 2 h to OD600 ~2. 1 mL of the cell cul-
ture was pelleted and resuspended in 100 μL YNB-DO. 
1 μL of the resuspended cells was mounted on 2 % low 
melting point agarose YNB-DO pads with a no. 1.5 cov-
erslip sealed with nail polish. Live yeast were imaged with 
a Leica SP5 confocal upright microscope at the Stanford 
Cell Sciences Imaging Facility equipped with a 63×, NA 
1.30 plan apochromat glycerine immersion objective. For 
fluorescence detection, the Argon laser 488  nm excita-
tion was used with descanned Hybrid-GaAsP detection 
at 500–600 nm. Imaging was done with either no zoom 
or 4.5× zoom and 80–120 % gain to avoid saturation.
Yeast culture assays for protoberberine alkaloid 
production
Single colonies of freshly transformed yeast strains were 
streaked onto YNB-DO agar, grown for 24  h, and then 
inoculated into 3 mL of the appropriate YNB-DO media 
and grown in 16 × 150 mm glass culture tubes for 17 h 
at 30  °C in a shaking incubator at 260  rpm. Overnight 
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cultures were back-diluted 1:20 into assay media com-
posed of YNB-DO media with 2  mM norlaudanosoline 
HBr (NL) to a total volume of 500 μL in culture tubes. 
Cultures were grown for 96 h and then pelleted by 5 min 
centrifugation. The supernatant was analyzed by high 
performance liquid chromatography–tandem mass spec-
trometry (LC–MS/MS). The optimization assays were 
performed with 1 mM norlaudanosoline HBr in 125-mL 
flasks in a total volume of 12.5 mL assay media with 2 % 
galactose or 2  % dextrose used as the sugar, either no 
buffer or 60 mM citrate buffer pH 5.7 was added, and cul-
tures were grown at 25 or 30 °C. To determine the cana-
dine and berberine titers of the cultures, 1 mL of culture 
was pelleted and the supernatant was analyzed by LC–
MS/MS as described below.
Analysis of protoberberine alkaloid production 
by high‑performance liquid chromatography–tandem 
mass spectrometry (LC–MS/MS)
Yeast media supernatants and yeast cell extracts were 
analyzed by LC–MS/MS using an Agilent 1260 infin-
ity binary pump HPLC and Agilent 6420 triple quadru-
pole mass spectrometer with an electrospray ionization 
source. Chromatography was performed with a Zorbax 
Eclipse Plus C18 column (2.1 × 50 mm, 1.8 μm, Agilent 
Technologies). Mobile phase A was water with 0.1 % for-
mic acid (FA), phase B was acetonitrile with 0.1  % FA, 
and the flow rate was 0.4 mL/min at 40 °C. 5 μL samples 
were injected and separated with the following method: 
10 % B for 0.1 min, 10–40 % B for 4.9 min, 40–98 % B 
for 1 min, held at 98 % B for 1 min, returned to 10 % B 
and re-equilibrate for 3 min. The LC eluent was directed 
to the MS for 1–5  min with ESI source gas tempera-
ture 350  °C, gas flow of 11  L/min, nebulizer pressure 
40 PSI, capillary voltage of 4000 V, and Delta EMV (+) 
of 200. Compound identity was confirmed by compar-
ing the retention time and product ion spectrum to 
an authentic standard when available or to published 
mass fragmentation spectra [15, 49] using MassHunter 
Qualitative Analysis v. B.06 (Agilent Technologies). For 
quantification, the MS was used in MRM mode to moni-
tor the transitions in Table  2. These transitions were 
determined using the MassHunter Optimizer software 
with standards when available or with samples with 
high abundance and confirmed with literature. The data 
was analyzed using MassHunter Quantitative Analy-
sis v. B.07 for QQQ (Agilent Technologies) to identify 
and integrate peaks with the qualifying and quantifying 
mass transitions and retention times (Table  2). Where 
available, quantifier MRM peak areas were compared 
to a calibration curve of external standard peak areas to 
determine concentration.
Batch and fed‑batch fermentations of engineered yeast 
strains
Batch and fed-batch fermentations were conducted in a 
Biostat Q-plus bioreactor with 0.5-L univessels (Sarto-
rius AG). Initial media was 0.2 L YNB-DO with 1  mM 
norlaudanosoline HBr and 60 mM citrate buffer, pH 5.7. 
Single colonies of freshly transformed yeast strains were 
streaked onto YNB-DO agar, grown for 24  h, and then 
inoculated into 3 mL of the appropriate YNB-DO media 
and grown in 16 × 150 mm glass culture tubes for 24 h 
at 30 °C in a shaking incubator at 260 rpm. Cultures were 
back-diluted 1:10 in 25  mL YNB-DO in 250-mL shake 
flasks and grown to OD 3.5–7, and then used to inocu-
late the bioreactor vessels to OD 0.3. Dissolved oxygen 
was calibrated at 100  % during 100  rpm stirring with 
0.1 lpm air flow. Process parameters were 30 °C and 25 % 
dissolved oxygen controlled by stirring at 100–400 rpm. 
Fermentation was begun with no air flow, and air flow 
was increased to 0.1 lpm when stirring reached 400 rpm, 
12–24  h. When stir rate dropped to 100  rpm and DO 
reached 80 %, air flow was turned off. Samples of ~1 mL 
were taken to measure OD600 and alkaloid concentra-
tions. OD600 of diluted culture samples was measured in 
cuvettes by Nanodrop spectrophotometer. For fed-batch, 
feed was 10× YNB-DO media, and feeding was begun at 
24 h at a rate of 20 mL/day, and continued for the remain-
der of the fermentation.
Table 2 MRM transitions used to quantify alkaloids in LC–MS/MS analysis
Compound Quantifier MRM transition Qualifier MRM transition
Precursor → product ion Fragmentor Collision 
energy
Precursor → product ion Fragmentor Collision 
energy
Reticuline 330 → 192 120 19 330 → 137 120 31
Scoulerine 328 → 151 135 30 328 → 178 135 29
Tetrahydrocolumbamine 342 → 178 135 29 342 → 163 135 29
Canadine 340 → 176 135 29 340 → 149 135 25
Berberine 336 → 320 135 29 336 → 292 135 25
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